Infantile Spasm Treatment Market - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Infantile spasm is a rare disorder that appears as seizures in infants below 1 year. Infantile spasm causes series of sudden, jerking movements of legs and arms or fast drop of head. The duration of spasm can last up to couple of seconds. Major drugs used for the treatment of infantile spasm include adrenocorticotropic hormone (ACTH), however, due to its side effects, doctors also prefer anti-seizure drugs such as vigabatrin and other steroid therapies.

Market Dynamics

Increasing prevalence of central nervous system infection, may develop infantile spasm which in turn is expected to boost the infantile spasm treatment market. According to the National Center for Biotechnology Information (NCBI), in January 2018, the prevalence of infantile spasm was 2 to 3.5 infants per 10,000 live births.

Government initiatives for rare disease treatment is expected to boost the market growth. For instance, The American Academy of Pediatrics also works with the Child Neurology Society, Child Neurology Foundation, American College of Emergency Physicians, and other partners to build advocacy, identify awareness gaps, and expand outreach opportunities.

The relapse or reoccurrence of infantile spasm is a major factor driving growth of the infantile spasm treatment market. According to investigators from Okayama University Hospital, Japan, after the treatment of infantile spasm with ACTH therapy for 11 to 37 days, the disease reoccurred in 41% of the people under study.

Moreover, the government of Brazil in year 2021 amended its regulatory rules for approving drugs for rare disease. In December 2021, Brazilian regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA) published Resolution RDC 205/2021, regulating special procedures for clinical trials, registration, and certification of Good Manufacturing Practices (GMPs) of drugs intended to treat, prevent or diagnose rare diseases such as infantile spasm.

Key features of the study:

• This report provides in-depth analysis of the infantile spasm treatment market and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global infantile spasm treatment market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include H. Lundbeck A/S, Mallinckrodt Pharmaceuticals, Catalyst Pharmaceuticals, GW Pharmaceuticals plc, Retrophin, Inc., Valerion Therapeutics, Orphelia Pharma SA, Insys Therapeutics, Inc., and Anavex Life Sciences Corp.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
• The global infantile spasm treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the infantile spasm treatment market

Detailed Segmentation:

• Global Infantile Spasm Treatment Market, By Product Type:
  • Adrenocorticotropic Hormone (ACTH)
  • Vigabatrin
  • Phase III
• Global Infantile Spasm Treatment Market, By Route of Administration:
  • Oral
  • Parenteral
• Global Infantile Spasm Treatment Market, By Region:
  • North America
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • U.S.
    • Canada
  • Latin America
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • By Product Type:
    • Adrenocorticotropic Hormone (ACTH)
    • Vigabatrin
    • Phase III
    • By Route of Administration:
    • Oral
    • Parenteral
    • By Country:
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • H. Lundbeck A/S*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Key Highlights
    • Market Strategies
  • Mallinckrodt Pharmaceuticals
  • Catalyst Pharmaceuticals
  • GW Pharmaceuticals plc
  • Retrophin, Inc.
  • Valerion Therapeutics
  • Orphelia Pharma SA
  • Insys Therapeutics, Inc.
  • Anavex Life Sciences Corp.

"*" marked represents similar segmentation in other categories in the respective section.